Hereditary Angioedema: When Twice-Monthly Attacks Justify Starting Long-Term Prophylaxis
Two attacks a month meets the guideline's own bar for starting prophylaxis. Whether that bar is actually the right one for a courtroom schedule that can't absorb a single missed morning is a different question.
She litigates for a living, which means her calendar is built months in advance and does not forgive last-minute cancellations — something she has had to explain to two different judges this year after hereditary angioedema attacks forced her to reschedule court appearances with essentially no warning. Her attacks have averaged twice a month over the past year, each one successfully managed with on-demand icatibant once it starts, but the unpredictability itself, not just the attacks, is what's actually costing her.
The current WAO/EAACI guideline is looser than the bright line clinicians tend to remember: it dropped the old fixed frequency trigger and now directs that every patient be evaluated for long-term prophylaxis at every visit, weighing disease activity, quality-of-life burden, and whether on-demand therapy alone is achieving adequate control. Her twice-monthly rate and two rescheduled court appearances speak to the second and third of those; what the guideline conspicuously does not supply is the number that would settle it for her. The complication isn't clinical ambiguity about whether she qualifies; it's that she has, in an earlier visit, said plainly she doesn't love the idea of adding a second regular injection on top of the on-demand medication she already carries, and a guideline threshold met on paper isn't the same as a decision she's actually ready to make.
Her disease was diagnosed in her twenties after a childhood of unexplained abdominal pain episodes that were, in hindsight, almost certainly undiagnosed abdominal HAE attacks; she has no other chronic medical conditions, and her C1-INH function and C4 levels have remained stably low and diagnostic on repeat testing rather than borderline. She mentioned that the abdominal attacks specifically, more than the peripheral swelling, are what she dreads most, since they've twice been mistaken for a surgical abdomen before her diagnosis was established years ago — a history that colors how she weighs any option promising fewer attacks overall, even one she isn't otherwise enthusiastic about starting.
A guideline threshold against her own stated preference
The HELP trial showed a large, consistent drop in attack frequency with lanadelumab, and the current guideline asks us to weigh disease activity, quality-of-life impact, and whether on-demand therapy alone is achieving adequate control — and on the third of those, two rescheduled hearings is a straightforward no. I'd recommend starting now rather than waiting for a worse attack to force the conversation.
I don't disagree with the guideline math, but she's told us directly she's not enthusiastic about a second regular injection on top of the on-demand therapy she already manages well. Meeting a frequency threshold on paper isn't the same as her being ready to take on that ongoing burden, and I don't think we should treat the number as automatically decisive.
Every attack so far has resolved with on-demand icatibant. The actual cost here is unpredictability and scheduling disruption, not treatment failure — and it's worth asking her directly whether prophylaxis or a different scheduling accommodation is the fix she'd actually choose.
That's a fair correction to how I framed it — the guideline threshold tells us she's a reasonable candidate, not that the decision is made. I'd still recommend it, but I agree it should be her call once she's heard the actual trade-off plainly, not something we start because the number says to.
Agreed: present lanadelumab as guideline-supported and clinically reasonable, but explicitly let her decide whether the added injection burden is worth trading for fewer, more predictable months, rather than starting it as the default outcome of today's visit.
She left with a two-week window to decide, continuing on-demand icatibant in the meantime — the guideline threshold and her own stated preference were both named plainly rather than one quietly overriding the other.